Andrew McConaghie reviews the findings of the latest pharma ranking index, which assesses on the premise: if you gave the same molecule to two different companies in early phase, which would ma
Novo Nordisk's pipeline drugs show 'astonishing' weight-loss effects – but can it convince sceptical payers that medicines are the answer to the obesity epidemic?
